Identification of clinical risk factors for histological progression of primary biliary cholangitis. Issue 9 (14th June 2019)

• Record Type: Journal Article
• Authors: Fujinaga, Yukihisa; Namisaki, Tadashi; Moriya, Kei; Kitade, Mitsuteru; Kawaratani, Hideto; Shimozato, Naotaka; Kaji, Kosuke; Takaya, Hiroaki; Sawada, Yasuhiko; Seki, Kenichiro; Akahane, Takemi; Okura, Yasushi; Sato, Shinya; Saikawa, Soichiro; Nakanishi, Keisuke; Kubo, Takuya; Furukawa, Masanori; Kitagawa, Koh; Ozutsumi, Takahiro; Tsuji, Yuki; Kaya, Daisuke; Mashitani, Tsuyoshi; Ishida, Koji; Ogawa, Hiroyuki; Takagi, Hirotetsu; Noguchi, Ryuichi; Mitoro, Akira; Yamao, Junichi; Yoshiji, Hitoshi
• Is Part Of: Hepatology research. Volume 49:Issue 9(2019)
• Page Start: 1015
• Page End: 1025
• Publication Date: 2019-06-14
• Subjects: gamma‐glutamyl transpeptidase -- primary biliary cholangitis -- risk factors -- ursodeoxycholic acid; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.13355
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: To identify laboratory predictors of histological progression (HP) of primary biliary cholangitis (PBC). Methods: Sequential biopsies were carried out on 35 (11.4%) of 308 patients with PBC treated with ursodeoxycholic acid (UDCA). Patients were divided into high γ‐glutamyl transpeptidase (GGT) ( n = 18) and low GGT ( n = 17) groups, based on the median value of GGT at baseline. Patients were then categorized as showing HP (progressive group, PG) or lacking HP (non‐progressive group, NPG) according to the Scheuer and Nakanuma classifications, with the latter grading liver fibrosis (fibrosis score) and bile duct loss (BDL score). Results: According to the Scheuer definition, 12 patients had HP and 23 did not. According to the Nakanuma definition, 8 and 27 patients were in the PG and NPG groups, respectively. The fibrosis and BDL scores progressed in 13 and 8 patients, respectively, whereas 22 and 25 patients did not show HP, respectively. Fisher's exact probability test analysis revealed that the rate of HP using the Nakanuma fibrosis score was significantly higher in the high GGT group compared to the low GGT group ( P < 0.05). However, no significant correlation was found between the HP of PBC and the biochemical response to UDCA therapy. Both univariate and multivariate logistic regression analyses indicated that the serum GGT level at baseline is an independent risk factor for an increased Nakanuma fibrosis score. Conclusions: The level of serum GGT at baseline is significantly associated with liver fibrosis progression in PBC, and therefore could help to predict the HP of PBC.